TR201803744T4 - Skleroderma tedavisinde kullanım için naltrekson içeren bileşimler. - Google Patents

Skleroderma tedavisinde kullanım için naltrekson içeren bileşimler. Download PDF

Info

Publication number
TR201803744T4
TR201803744T4 TR2018/03744T TR201803744T TR201803744T4 TR 201803744 T4 TR201803744 T4 TR 201803744T4 TR 2018/03744 T TR2018/03744 T TR 2018/03744T TR 201803744 T TR201803744 T TR 201803744T TR 201803744 T4 TR201803744 T4 TR 201803744T4
Authority
TR
Turkey
Prior art keywords
scleroderma
treatment
compositions containing
containing naltrexone
naltrexone
Prior art date
Application number
TR2018/03744T
Other languages
English (en)
Inventor
Levent Selamoğlu Mehmet
Bi̇ngöl Semra
Mustafa İskender Pisak İbrahi̇m
Nevzat Pi̇sak Mehmet
Original Assignee
Imuneks Farma Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imuneks Farma Ilac Sanayi Ve Ticaret Anonim Sirketi filed Critical Imuneks Farma Ilac Sanayi Ve Ticaret Anonim Sirketi
Publication of TR201803744T4 publication Critical patent/TR201803744T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Naltrekson, nalokson veya nalmefen gibi opioid antagonistlerini ya da farmasötik olarak kabul edilebilir tuzlarını içeren bileşimler ve bunların sistemik skleroz dahil skleroderma tedavisinde kullanımı tarif edilmektedir.
TR2018/03744T 2011-03-31 2011-03-31 Skleroderma tedavisinde kullanım için naltrekson içeren bileşimler. TR201803744T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/TR2011/000075 WO2012134410A1 (en) 2011-03-31 2011-03-31 Compositions of opioid antagonists and their use for treating scleroderma

Publications (1)

Publication Number Publication Date
TR201803744T4 true TR201803744T4 (tr) 2018-07-23

Family

ID=44120869

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2018/03744T TR201803744T4 (tr) 2011-03-31 2011-03-31 Skleroderma tedavisinde kullanım için naltrekson içeren bileşimler.

Country Status (8)

Country Link
EP (1) EP2691097B1 (tr)
JP (1) JP5738470B2 (tr)
BR (1) BR112013024137A2 (tr)
CA (1) CA2829280C (tr)
MX (1) MX2013010371A (tr)
RU (1) RU2552290C1 (tr)
TR (1) TR201803744T4 (tr)
WO (1) WO2012134410A1 (tr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140005216A1 (en) 2012-06-27 2014-01-02 H. Lundbeck A/S Nalmefene for reduction of alcohol consumption in specific target populations
CN109475626A (zh) * 2016-07-14 2019-03-15 儿童医院医疗中心 治疗纤维化的方法
WO2024074963A1 (en) * 2022-10-03 2024-04-11 Naltrexone Therapeutics, Inc. Pharmaceutical compositions and methods

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356900A (en) 1986-10-07 1994-10-18 Bernard Bihari Method of treating chronic herpes virus infections using an opiate receptor antagonist
US4888346A (en) 1986-10-07 1989-12-19 Bernard Bihari Method for the treatment of persons infected with HTLV-III (AIDS) virus
RU2190406C2 (ru) * 1998-03-12 2002-10-10 Казанский государственный медицинский университет Способ лечения псориаза
RU2289441C2 (ru) * 2002-06-24 2006-12-20 Казанский государственный медицинский университет Способ лечения системной склеродермии
US8524731B2 (en) * 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US20120252831A1 (en) * 2011-03-31 2012-10-04 Mustafa Nevzat Ilac Sanayii A.S. Compositions of opioid antagonists and methods for treating scleroderma therewith

Also Published As

Publication number Publication date
EP2691097A1 (en) 2014-02-05
BR112013024137A2 (pt) 2017-09-26
CA2829280C (en) 2016-05-24
WO2012134410A1 (en) 2012-10-04
RU2552290C1 (ru) 2015-06-10
JP2014510112A (ja) 2014-04-24
JP5738470B2 (ja) 2015-06-24
EP2691097B1 (en) 2017-12-20
MX2013010371A (es) 2014-02-28
CA2829280A1 (en) 2012-10-04

Similar Documents

Publication Publication Date Title
EA201400246A1 (ru) Новая, не допускающая злоупотребления фармацевтическая композиция для лечения опиоидной зависимости
CL2013002177A1 (es) Compuestos derivados de 9h-purinas y 7h-pirrolo[2,3-d]-pirimidinas sustituidas, inhibidores de la pi3k de clase i y/o mtor; su composicon farmaceutica; su combinacion farmaceutica; y su uso en el tratamiento o la prevencion del cancer o trastornos neurodegenerativos.
PH12020500255A1 (en) Use of nk-1 receptor antagonist serlopitant in pruritus
SG194469A1 (en) Tetrahydroquinoline derivatives useful as bromodomain inhibitors
IN2014DN10670A (tr)
PH12015500088A1 (en) Process for improved opioid synthesis
IN2015DN01165A (tr)
MX2013008225A (es) Composicion farmaceutica que comprende agonistas de opioide y antagonista secuestrado.
MX347105B (es) Composiciones farmaceuticas que comprenden hidromorfona y naloxona.
MX2016004741A (es) Composicion farmaceutica que comprende un antagonista de trpa1 y un agente analgesico.
UA115357C2 (uk) Похідні піридин-4-ілу
MY161601A (en) Films and compositions comprising the same
WO2014153495A3 (en) Novel stat3 inhibitors
UA116405C2 (uk) Гідроморфон та налоксон для лікування болю та синдрому опіоїдної дисфункції кишечнику
TR201002473A2 (tr) Herpes zoster hastalığının bır opiat reseptör antagonist kullanılarak tedavi yöntemi.
PH12015500185B1 (en) Azaheterocycles as bir2 and/or bir3 inhibitors
TR201803744T4 (tr) Skleroderma tedavisinde kullanım için naltrekson içeren bileşimler.
MX367773B (es) Forma salina sólida de la alfa-6-mpeg6-o-hidroxicodona como agonistas opioides y sus usos.
IN2014DN09359A (tr)
TN2014000484A1 (en) Dronedarone for use in leishmaniasis, formulations and associations for use in leishmaniasis.
IN2013MU02852A (tr)